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Abstract: The hyperphosphorylation of the microtubule-associated protein tau (MAPT) has been
implicated in various neurological diseases, including Alzheimer’s disease. It has been hypothesized
that the reduction of MAPT would result in depolymerizing neurofibrillary tangles and could be
a potential strategy for the treatment of Alzheimer’s disease and other tauopathies. In this study,
we report the development of novel DNAzymes and splice-modulating antisense oligonucleotides
(AOs) for the efficient inhibition of MAPT. We designed and synthesized a range of DNAzymes and
2′-O-methyl (2’-OMe)-modified AOs on a phosphorothioate (PS) backbone targeting various exons
across the MAPT gene transcript. Our results demonstrated that RNV563, an arm-loop-arm-type
DNAzyme targeting exon 13, and an AO candidate AO4, targeting exon 4, efficiently downregulated
MAPT RNA expression by 58% and 96%, respectively. In addition, AO4 also reduced the MAPT
protein level by 74%. In line with our results, we believe that AO4 could be used as a potential
therapeutic molecule for Alzheimer’s disease and other tauopathies.
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1. Introduction
Synthetic nucleic acid-based technologies offer great promise for the development of precision
therapeutics for the treatment of various diseases. So far, nine oligonucleotide drug molecules
have been approved for clinical use, including Vitravene for viral retinitis, Macugen for age-related
macular degeneration, Kynamro for familial hypercholesterolemia, Exondys51 and Vyondys53 for
Duchenne muscular dystrophy, Spinraza for spinal muscular atrophy, Onpattro and Tegsedi for
hereditary transthyretin amyloidosis, and Waylivra for familial chylomicronemia syndrome [1,2].
Inspired by the rapid progress in the translation of nucleic acid drugs in recent years, we envisioned
the development of novel nucleic acid molecules for targeting the microtubule-associated protein tau
(MAPT), which is a protein that belongs to the microtubule-associated protein family [3]. The aggregation
of hyperphosphorylated tau that leads to the formation of neurofibrillary tangles has been implicated in
a variety of tauopathies, including Alzheimer’s disease (AD), frontotemporal dementia, Pick disease,
argyrophilic grain disease, progressive supranuclear palsy, and corticobasal degeneration [3]. There are
six isoforms of tau found in the adult brain produced through alternative splicing of the MAPT
pre-mRNA [4,5] (Figure S9, Supplementary Material). Three of the isoforms have a three-repeat segment
in the microtubule binding domain, while the other three have a four-repeat segment in the microtubule
binding domain, and both groups are found in equal amounts in the adult brain [4,5].
Genes 2020, 11, 667; doi:10.3390/genes11060667 www.mdpi.com/journal/genes
Genes 2020, 11, 667 2 of 15
Tau levels are found to be elevated in the cerebrospinal fluid of AD patients. Although neurofibrillary
tangles are a hallmark of AD, most drug development initiatives have targeted the amyloid beta
pathway. However, due to the failure of drug molecules targeting the amyloid beta pathway, the focus
is now shifting towards targeting hyperphosphorylated tau. One approach is the development of
antisense oligonucleotides (AOs) against MAPT to reduce the production of hyperphosphorylated tau.
A gapmer AO named MAPTRX developed by IONIS Pharmaceuticals is currently being tested in Phase
II clinical trials [6]. Another study evaluated phosphorodiamidate morpholino oligomers (PMOs) for
downregulating tau expression in human neuroblastoma cells [7]. Although it is believed that tau
plays a very important role in stabilizing microtubules (loss of this function has been attributed to
neurodegeneration), mouse models have shown that tau knockout is well-tolerated and these mice only
develop minor motor phenotypes at 12–16 months after tau knockout [8]. Furthermore, reducing tau
levels in adult mice does not result in behavioral or neuroanatomical abnormalities, indicating that there
may be other microtubule-associated proteins that can compensate for the loss of tau in microtubule
stabilization [8,9]. Furthermore, it has been hypothesized that the reduction in tau monomers may
result in depolymerization of the paired helical filaments to maintain equilibrium [9]. In this study,
we developed novel DNAzymes and 2’-O-methyl (2’-OMe) phosphorothioate (PS) RNA-modified
(Figure 1) steric blocking AOs targeting various MAPT exons for the efficient downregulation of tau
protein levels.
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They possess catalytic activity, through which they degrade their target by cleavage of the 
phosphodiester bond at the purine–pyrimidine junction or at the purine–purine junction [14–17]. 
DNAzymes require divalent metal ions as cofactors for their catalytic activity similar to naturally 
occurring enzymes [14]. Unlike RNase-H-dependent AOs, DNAzymes do not require RNase-H 
recruitment for target mRNA cleavage. 
Steric-blocking AOs bind to the target mRNA and can block the access of cellular machinery to 
pre-mRNA and mRNA, and can therefore modulate splicing, repair defective RNA, restore protein 
production, or downregulate gene expression without degrading the RNA [18–20]. Steric-blocking 
AOs that modulate splicing have been approved for clinical use for the treatment of Duchene 
muscular dystrophy and spinal muscular atrophy [21,22]. Splice-modulating AOs bind to their 
complementary mRNA targets through Watson–Crick base pairing and modulate splicing through 
blocking the interaction of the pre-mRNA with splicing factors such as RNA-binding proteins, small 
nuclear RNAs, and other components of the spliceosome [23].  
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DNAzymes with stem-loop conformation were designed for the selected exons (Table S1, 
Supplementary Material), in line with our previous work on antimiRzymes [24], and the 
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DNAzymes are a unique class of oligonucleotides that have catalytic activity and can be
used for various applications, including gene silencing, and in diagnostic tools as biosensor
molecules [10–13]. DNAzymes bind to their complementary mRNA targets through Watson–Crick
base pairing. They possess catalytic activity, through which they degrade their target by cleavage of
the phosphodiester bond at the purine–pyrimidine junction or at the purine–purine junction [14–17].
DNAzymes require divalent metal ions as cofactors for their catalytic activity similar to naturally
occurring enzymes [14]. Unlike RNase-H-dependent AOs, DNAzymes do not require RNase-H
recruitment for target mRNA cleavage.
Steric-blocking AOs bind to the target mRNA and can block the access of cellular machinery to
pre-mRNA and mRNA, and can therefore modulate splicing, repair defective RNA, restore protein
production, or downregulate gene expression without degrading the RNA [18–20]. Steric-blocking
AOs that modulate splicing have been approved for clinical use for the treatment of Duchene muscular
dystrophy and spinal muscular atrophy [21,22]. Splice-modulating AOs bind to their complementary
mRNA targets through Watson–Crick base pairing and modulate splicing through blocking the
interaction of the pre-mRNA with splicing factors such as RNA-binding proteins, small nuclear RNAs,
and other components of the spliceosome [23].
2. Materials and Methods
2.1. DNAzymes and AOs
DNAzymes with stem-loop conformation were designed for the selected exons (Table S1,
Supplementary Material), in line with our previous work on antimiRzymes [24], and the oligonucleotides
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were ordered from Integrated DNA Technologies (IDT, Singapore). AOs (uniformly 2’-OMePS modified)
were designed and synthesized for the selected exons, in line with our previous work on Duchenne
muscular dystrophy (DMD) [25–31]. The DNAzymes and 2’-OMePS AOs were designed to target the
selected exons of MAPT variant 2, which is the longest isoform found in the adult brain. The 2’-OMePS
AOs were synthesized in-house on the AKTA Oligopilot 10 synthesizer (GE Healthcare Life Sciences,
Chicago, USA) using standard phosphoramidite chemistry at a 1 µmole scale (AO names and their
sequences are listed in Table S3, Supplementary Material). The synthesized AOs were deprotected
by treatment with 1 mL ammonium hydroxide (Sigma, Castle Hill, Australia; Cat# 221228-500mL)
overnight at 55 ◦C and were purified by desalting using the illustra NAP-10 columns (GE Healthcare;
Cat# 45-000-153), according to the manufacturer’s protocol and verified by HPLC.
2.2. Cell Culture and Transfection of AOs and DNAzymes
Cell culture media and supplements were purchased from Life technologies, Australia, unless
specified. SH-SY5Y cells were obtained from Cell Bank Australia (kindly provided by Prof. Sue Fletcher
and Prof. Steve Wilton). SH-SY5Y cells were propagated in Dulbecco’s modified Eagle’s medium: F12
medium and 10% fetal bovine serum (Serana, Wembley, Australia; Cat# FBS-AU-015) in a humidified
atmosphere in a 37 ◦C incubator with 5% CO2. Cells were maintained at 70–90% confluency and
seeded onto a plate or flask for transfections. Transfections were performed in 24 well-plate formats
with approximately 70,000 cells/well for RNA transcript analysis. Transfections were also performed in
T25 cm2 format with approximately 875,000 cells/well for protein analysis. The cells were seeded one
day before being transfected with the DNAzymes or 2’-OMePS AOs complexed with Lipofectamine
3000 transfection reagent (ThermoFisher Scientific, Malaga, Australia; Cat# L3000015), as per the
manufacturer’s protocol. Transfection was carried out for 24 h before harvesting RNA for transcript
analysis. For protein analysis, transfection was carried out 24 h, 48 h (re-transfected at 24 h), and six
days (re-transfected at 24 and 48 h) before collecting the cell pellet.
2.3. RT-PCR Analysis of AOs and DNAzymes Treatment
Total RNA was extracted using the Bioline Isolate II RNA MiniPrep Kit (Bioline, Eveleigh, Australia;
Cat# BIO-52073), following the manufacturer’s protocol. A total of 50 ng of total RNA was analysed
using primer sets (ordered from IDT) listed in Table S4 of Supplementary Material, in the Superscript
III One-Step RT-PCR System (ThermoFisher Scientific; Cat# 12574026), and the reaction conditions are
given in Table S5 of Supplementary Material. The primers used to perform the RT-PCR were designed
to amplify the longest MAPT isoform—variant 2. GAPDH was used as a loading control and the
primer set (ordered from IDT), and RT-PCR conditions for GAPDH are given in Tables S4 and S5 of
Supplementary Material. The products were separated on a 2% agarose gel in Tris-acetate-EDTA buffer,
stained with Red Safe (iNtRON Biotechnology, Seongnam, South Korea; Cat# 21141), and destained
with water, before being visualized with the Fusion Fx gel documentation system (Vilber Lourmat,
Collégien, France).
2.4. Densitometry Analysis
Densitometry (measuring the band intensity) of the bands from the gels was performed using
Image J Software [32]. The intensity of the MAPT bands (longest MAPT isoform, variant 2) in different
DNAzyme- or AO-treated samples was measured and normalized to the intensity of the corresponding
GAPDH bands, before being compared to the band intensity of the scrambled samples or untreated
samples. The percentage of the longest MAPT isoform, calculated as variant 2 transcript knockdown in
SH-SY5Y cells, was expressed as the activity of DNAzyme or AO. All percentages given in this study
refer to the longest MAPT isoform—variant 2.
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2.5. In Vitro Cleavage Assay Using DNAzymes
The cleavage efficiency of the second-generation DNAzymes in vitro was tested using the
in vitro cleavage assay. A synthetic fluorescein dye (FAM)-labeled RNA target specific to the
exon 11 region of the MAPT transcript was used. The experiments were performed by incubating
DNAzymes RNV563 and their second-generation variants with an FAM-labeled RNA template in
the presence of divalent metal ions, and the products were separated and analysed on a denaturing
polyacrylamide gel. A total of 1.76 µM DNAzymes was incubated with an equal molar concentration of
FAM-conjugated MAPT RNA (5′-FAM-UGUGGCUCAUUAGGCAACAUCCAUCAUAAACCAG-3′)
in 5 µL of buffer containing Mg2+ divalent cations (10 mM MgCl2) at 37 ◦C. The reaction was stopped
by adding 10 µL of formamide to 10 µL of the reaction mixture at 0 min, 30 min, 60 min and 2 h.
Scrambled DNAzyme RNV563-SCR (AACATCCTCGTTGTAGCTAGCCTCATAAAC), RNV563-Mut1
(GTTTATGAAACTAGCTACAACGAGGATGTT), and RNV563-Mut2 (GTTTATGAGGCTAAATA
CAACGAGGATGTT) were used as negative controls, and the untreated samples did not have any
DNAzyme. The underlined bases are the mutated bases and the two double mutants RNV563-Mut1
and RNV563-Mut2 were designed based on previous papers [33,34]. The reaction mixtures were
separated on a 15% polyacrylamide gel/7M urea for 50 mins at 13 W. The gel was visualized using the
Fusion Fx gel documentation system (Vilber Lourmat, Collégien, France). The cleavage of the 34mer
full-length FAM-conjugated RNA target is expected to yield 22 nucleotide-long products.
2.6. Western Blot
Western blot analysis was performed on the best performing AO to evaluate the effect of the
AO on the inhibition of the MAPT protein in comparison to the scrambled AO-treated and untreated
samples. Frozen transfected cell pellets were thawed and homogenized in SDS lysis buffer (0.5 M
Tris-HCL pH 6.8, 3% SDS (w/v), and 10% glycerol (v/v)) containing protease inhibitor (Sigma, Castle Hill,
Australia). The proteins were separated on a 10% polyacrylamide gel containing 400 mM Tris-HCL
(pH 8.8) and 0.1% SDS in a Tris-glycine-SDS running buffer, before being transferred to a 0.2 µm
nitrocellulose membrane (Biorad, Gladesville, Australia; Cat# 162-0112) in a Tris-glycine-methanol
transfer buffer. The membranes were blocked in 5% skim milk Tris-buffered saline with 0.1%
Tween. The membrane was washed in Tris-buffered saline with 0.1% Tween, and incubated with
primary antibodies overnight at 4 ◦C, 1:2000 anti-total tau (Abcam, Cambridge, UK; Cat# ab76128),
and 1:1000 anti-GAPDH (ThermoFisher Scientific, Malaga, Australia; Cat# PA1-988). After washing the
membrane in Tris-buffered saline with 0.1% Tween, the membrane was incubated with the secondary
antibody (1:5000 anti-rabbit HRP, Thermofisher Scientific, Malaga, Australia; Cat# 31460) for 1 h
at room temperature before washing. The antibodies were detected using a Clarity Western ECL
detection kit (Biorad, Gladesville, Australia; Cat# 1705060) according to the manufacturer’s protocol
and visualized using a chemiluminescence-based protocol on the Fusion Fx gel documentation system
(Vilber Lourmat, Collégien, France).
3. Results
3.1. Design and Screening of DNAzymes Targeting MAPT mRNA
Arm-loop-arm-type DNAzymes with a 10–23 catalytic motif were designed to target various
exons of the MAPT transcript (Table S1, Supplementary Material). The sequences of the catalytic
regions were pre-fixed according to previous reports [35,36] and the arm regions were designed to
be specific and complementary to the MAPT mRNA sequences. Initially, the catalytic activities of
all the designed DNAzymes against MAPT mRNA were screened in SH-SY5Y neuroblastoma cells
by transfecting at two different concentrations (400 and 50 nM) for 24 h. Total RNA was extracted
from the cell lysate, and the integrity of the MAPT transcript was assessed by performing RT-PCR.
Dose-dependent reduction of the full-length MAPT transcript was observed at various levels for
RNV559, RNV561, RNV563, RNV569, RNV570, and RNV571 DNAzyme candidate-treated samples
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(Figure S1, Supplementary Material). The best MAPT transcript knockdown was observed for RNV559,
RNV561, RNV563, and RNV569 DNAzymes at 400 nM. The catalytic activities of RNV559, RNV561,
RNV563, and RNV569 were further validated against MAPT mRNA in SH-SY5Y cells at four different
concentrations, including 50, 100, 200, and 400 nM (Figure 2). DNAzyme candidate RNV563 targeting
the exon 11 of the MAPT mRNA showed the highest efficacy, with 58% knockdown of MAPT mRNA,
followed by RNV561 (26%) (Figure 2A; densitometry analysis in Figure S2B of Supplementary Material).
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Figure 2. RT-PCR analysis of DNAzymes RNV559, RNV561, RNV563, and RNV569 treated SH-SY5Y
cells. (A) Representative RT-PCR products of the microtubule-associated protein tau (MAPT) and
GAPDH transcripts from SH-SY5Y cells after treatment with DNAzyme RNV559, RNV561, RNV563,
and RNV569 at 400, 200, 100, and 50 nM concentrations. (B) The average activity of first-generation
DNAzymes (at a 400 nM concentration) in SH-SY5Y cells (knockdown of the MAPT transcript).
The erage activity was obtained throug three replicates. The error bars represent the standard error
of the mean. RNA from RNV559- and RNV561-treated samples wa analysed using primer set
3 and the RNA from RNV563- and RNV569-treated samples was analysed using primer set 4. FL,
full-l gth; T, ntreated. GAPDH was used as a loading control. Th gel images we e cropped to
highlight the MAPT-specific products and the corresponding house-keeping gene control GAPDH.
The original images are shown in Figure S2 (Supplementary aterial).
3.2. Design a d Screening of Second-Generation s rgeting MAPT mRNA
Based on the initial screeni g outputs, the est erfor ing DNAzyme RNV563 was selected for
further modifications in order to improve the efficacy by systematically increasing and decreasing
the binding arm lengths. Many studies have shown that modifying the length of the hybridization
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arms on either side of the catalytic motif can increase the binding affinity and efficacy [37–39]. In our
study, the first generation of DNAzymes initially had eight nucleotides on one arm and seven on the
other. Several studies have shown that the optimal arm lengths vary from 7 to 10 nucleotides long.
Therefore, the length of RNV563 was increased by one to three nucleotides at the end of both arms and
named RNV610, RNV611, and RNV612 (Table 1), and the efficacy of the modified DNAzymes was then
verified. Additionally, we decreased the arm length of our first-generation DNAzyme RNV563 and
verified the efficacy of the shorter DNAzymes by removing one and two nucleotides from both ends
and naming them RNV608 and RNV609 (Table 1). The catalytic activities of these second-generation
DNAzyme candidates were analysed in SH-SY5Y as described above. The transfections were repeated
three times. Decreasing the length of the RNV563 completely abolished the DNAzyme activity of
RNV608 (0%) and RNV609 (0%), even at 600 nM, compared to the parent DNAzyme RNV563 (56%).
Furthermore, increasing the length of the RNV563 also reduced the DNAzyme activity of RNV610
(11%), RNV611 (1%), and RNV612 (6%) (Figure S3 and Table S2, Supplementary Material). These results
showed that increasing and decreasing the arm length abolished the efficacy of DNAzyme RNV563 in
SH-SY5Y cells.
Table 1. Second-generation DNAzymes derived from the first-generation parent DNAzyme RNV563,
their sequences, and their target sequence.
Name Sequence 5’→3’ Target Sequence
RNV563 GTTTATGA GGCTAGCTACAACGA GGATGTT AACATCCATCATAAAC
RNV608 TTTATGA GGCTAGCTACAACGA GGATGT ACATCCATCATAAA
RNV609 TTATGA GGCTAGCTACAACGA GGATG CATCCATCATAA
RNV610 GGTTTATGA GGCTAGCTACAACGA GGATGTTG CAACATCCATCATAAACC
RNV611 TGGTTTATGA GGCTAGCTACAACGA GGATGTTGC GCAACATCCATCATAAACCA
RNV612 CTGGTTTATGA GGCTAGCTACAACGA GGATGTTGCC GGCAACATCCATCATAAACCAG
3.3. In Vitro Cleavage of the MAPT RNA Template
To further verify and understand the catalytic activity of DNAzymes targeting the MAPT transcript,
we tested the cleavage efficacy in vitro using a synthetic fluorescein dye (FAM)-labeled RNA target
specific to the exon 11 region of the MAPT transcript. The experiments were performed by incubating
DNAzymes RNV563 and their second-generation variants with an FAM-labeled RNA template in
the presence of divalent metal ions, and the products were separated and analysed on a denaturing
polyacrylamide gel. Briefly, 1.76 µM DNAzymes was incubated with 1.76 µM FAM-conjugated MAPT
RNA in the presence of Mg2+ for 30, 60, and 120 min at 37 ◦C. The reactions were stopped by adding
10 µL of formamide solution. The products were then separated on a 15% denaturing polyacrylamide
gel and visualized using the Fusion Fx gel documentation system (Vilber Lourmat). The cleavage of
the 34mer full-length FAM-conjugated RNA target is expected to yield 22 nucleotide-long products.
A scrambled (SCR) sequence and RNV563 mutants with different mutations (RNV563Mut1 and
RNV563Mut2) within the catalytic region of RNV563 were used as negative controls in parallel and
an untreated (UT) sample with no DNAzyme was also included. DNAzymes RNV563, RNV610,
RNV611, and RNV612 showed efficient cleavage of the MAPT RNA template in vitro, whereas the
RNV608 and RNV609 with decreased arm lengths failed to yield any RNA cleavage (Figure 3).
Notably, the in vitro cleavage rates of the DNAzymes with increased arm lengths, RNV610, RNV611,
and RNV612, were faster than that of their parent DNAzyme, RNV563. As expected, the scrambled
control and the mutant RNV563 did not show any cleavage (Figure 3).
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Figure 3. In vitro cleavage of the synthetic fluorescein dye (FAM)-conjugated MAPT RNA template
by RNV563 and its derivatives. The table provides the catalytic activity. FL RNA, full-length
FAM-conjugated RNA; cleaved RNA, cleaved FAM-conjugated MAPT RNA (22 nucleotides long).
The FAM-conjugated template RNA is a small region of the MAPT transcript complementary to the
hybridization arms of the DNAzymes. The gel images were cropped for a better overview. The original
images are shown in Figure S4 (Supplementary Material).
3.4. Evaluation of Splice odulating AOs to Induce Exon-Skipping in the MAPT Transcript
Firstly, we evaluated the exon-skipping efficiency of all AOs targeting different exons (Table S3,
Supplementary Material) in vitro at two different concentrations (400 and 50 nM). The results
demonstrated that AO4, AO5, AO6, and AO19 targeting exons 4, 5, and 19 resulted in exon-skipping and
downregulation of the MAPT transcript in vitro (Figure S5, Supplementary Material). AO4, AO5, AO6,
and AO19 were further validated at 400, 200, 100, and 50 nM (Figure 4A; see Figure 4C for densitometry
analysis). The results showed that AO4 (92%), AO5 (83%), AO6 (93%), and AO19 (74%) were all efficient
at downregulating MAPT transcript levels (Figure 4A,C), even at the lowest concentration (50 nM)
tested, compared to the scrambled control. AO4 (20%) and AO5 (27%) induced MAPT exon 4 skipping.
AO6 treatment of SH-SY5Y cells resulted in MAPT exon 5 skipping (71%) at a 50 nM concentration
(Figure 4A,C). The AO4, AO5, AO6, and AO19 were further tested at lower concentrations, including
50, 25, 12.5, and 6.25 nM, with GAPDH as a loading control as they showed downreg lation of the
MAPT transcript at the higher concentrations (Figure 4B; see Figure 4D for densitometry analysis).
Notably, AO4 (20%) nd AO5 (27%) induced MAPT exon 4 skipping and wer most effici nt at 25 nM.
In addition, AO4 (96%) and O5 (76%) also resulted in d e-dependent dow regula ion of the MAPT
transcript and wer most efficient at 50 nM. Although AO19 downregulated the MAPT transcript,
it failed to demonstrate dose-dependent inhibition. AO4 was further validated in inhibiting the
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expression of the MAPT protein as it was found to be the most efficient candidate at inhibiting the
MAPT transcript.
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SCR AO was at 50 nM. (C) Densitometry analysis of RT-PCR products (three replicates) normalized 
to the SCR control using AO4, AO6, AO7m and AO19 showed downregulation and exon-skipping of 
the MAPT transcript in SH-SY5Y cells in vitro. Concentrations of AOs used include 400, 200, 100, and 
50 nM, with an SCR concentration of 400 nM. The error bars represent the standard error of the mean. 
(D) Densitometry analysis of RT-PCR products (three replicates) normalized to the SCR control using 
AO4, AO6, AO7, and AO19 showed downregulation and exon-skipping of the MAPT transcript in 
SH-SY5Y cells in vitro. Concentrations of AOs used include 50, 25, 12.5, and 6.25 nM, with an SCR 
concentration of 50 nM. The error bars represent the standard error of the mean. AO4 targets exon 4, 
AO5 and AO6 target exon 5, and AO19 targets exon 12 of the MAPT transcript. RNA from AO4-, 
AO5-, and AO6-treated samples was analysed using primer set 2. RNA from AO19-treated samples 
was analysed using primer set 4. FL, full-length; UT, untreated; SCR, scrambled sequence. GAPDH 
was used as a loading control. The gel images were cropped to highlight the MAPT-specific products 
and the corresponding house-keeping gene control GAPDH. The original images are shown in Figure 
S6 (Supplementary Material). 
3.5. Evaluation of MAPT Protein Downregulation Using AO4 
To further evaluate the efficacy of AO4 and RNV563 in inhibiting MAPT expression, the total 
MAPT protein level was evaluated in SH-SY5Y cells after 24 h, 48 h, and six days of transfection with 
Figure 4. (A) Representative RT-PCR products of the MAPT and GAPDH transcripts from SH-SY5Y cells
after treatment with AO4, AO5, AO6, and AO19 at 400, 200, 100, and 50 nM concentrations. Treatment
with a scrambled sequence (SCR) antisense oligonucleotide (AO) was at 400 nM. (B) Representative
RT-PCR products of the MAPT and GAPDH transcripts from SH-SY5Y cells after treatment with AO4,
AO5, AO6, and 19 at 50, 25, 12.5, and 6.25 nM concentrations. Treatment with SCR AO was at 50 nM.
(C) Densitometry a alysis of RT-PCR products (three replicates) normaliz d to the SCR control using
AO4, AO6, AO7m and AO19 showed downregulation and ex n-skipping of the MAPT transcript in
SH-SY5Y cells in vi ro. Concentrations of AOs us d include 400, 200, 100, and 5 nM, with SCR
concentration of 400 nM. The error bars repres nt the standa d rror of the mean. (D) Densitometry
analysis of RT-PCR products (three replicate ) normalized to the SCR con rol using AO4, AO6, AO7,
and AO19 showed downregulation and exon-skippi g of the MAPT transcript in SH-SY5Y cells in vitro.
Concentrations of AOs used include 50, 25, 12.5, and 6.25 nM, with an SCR concentration of 50 nM.
The error bars represent the standard error of the mean. AO4 targets exon 4, AO5 and AO6 target exon
5, and AO19 targets exon 12 of the MAPT transcript. RNA from AO4-, AO5-, and AO6-treated samples
was analysed using primer set 2. RNA from AO19-treated samples was analysed using primer set 4. FL,
full-length; UT, untreated; SCR, scrambled sequence. GAPDH was used as a loading control. The gel
images were cropped to highlight the MAPT-specific products and the corresponding house-keeping
gene control GAPDH. The original images are shown in Figure S6 (Supplementary Material).
3.5. Evaluation of MAPT Protein Downregulation Using AO4
To further evaluate the efficacy of AO4 and RNV563 in inhibiting MAPT expression, the total
MAPT protein level was evaluated in SH-SY5Y cells after 24 h, 48 h, and six days of transfection with
AO4 and RNV563. Briefly, AO4- and RNV563-treated SH-SY5Y cells were incubated for 24 h, 48 h,
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and six days before collection. The cell pellet was collected and lysed, and the proteins were separated
on a 10% separating gel and transferred onto a nitrocellulose membrane. The membrane was incubated
with 1:2000 dilution of the MAPT (total tau) antibody overnight at 4 ◦C. The results clearly demonstrated
that there was downregulation of the MAPT gene transcript and MAPT protein in cells 24 h, 48 h,
and six days after AO4 treatment; however, the highest MAPT protein downregulation (74%) was seen
six days after transfection (Figures 5 and 6A for densitometry analysis). The results also demonstrated
that there was downregulation of the MAPT protein in cells 24 and 48 h after RNV563; however the
MAPT protein was close to MAPT protein levels in untreated and scrambled control-treated cells after
six days of incubation. The highest MAPT protein downregulation (50%) was seen 48 hours after
RNV563 transfection (Figure 6B for densitometry analysis, Figure S9B, Supplementary Material for
western blot analysis).
Genes 2019, 10, x FOR PEER REVIEW 9 of 15 
 
AO4 and RNV563. Briefly, AO4- and RNV563-treated SH-SY5Y cells were incubated for 24 h, 48 h, 
and six days before collection. The cell pellet was collected and lysed, and the proteins were separated 
on a 10% separating gel and transferred onto a nitrocellulose membrane. The membrane was 
incubated with 1:2000 dilution of the MAPT (total tau) antibody overnight at 4 °C. The results clearly 
demonstrated that there was downregulation of the MAPT gene transcript and MAPT protein in cells 
24 h, 48 h, and six days after AO4 treatment; however, the highest MAPT protein downregulation 
(74%) was seen six days after transfection (Figure 5 and Figure 6A for densitometry analysis). The 
results also demonstrated that there was downregulation of the MAPT protein in cells 24 and 48 h 
after RNV563; however the MAPT protein was close to MAPT protein levels in untreated and 
scrambled control-treated cells after six days of incubation. The highest MAPT protein 
downregulation (50%) was seen 48 hours after RNV563 transfection (Figure 6B for densitometry 
analysis, Figure S9B, Supplementary Material for western blot analysis).  
 
Figure 5. (A) Representative RT-PCR products of the MAPT transcripts from SH-SY5Y cells after 
treatment with an AO4 50 nM concentration and incubation of AO for 24 h, 48 h, and six days. RNA 
from AO4-treated samples was analysed using primer set 2. (B) Representative protein products of 
the MAPT and GAPDH transcripts from SH-SY5Y cells after treatment with AO4 at 50 nM 
concentrations and incubation of AO for 24 h, 48 h, and six days. RT-PCR products of the MAPT 
transcripts and protein products of the MAPT and GAPDH transcripts from SH-SY5Y cells after 
treatment with SCR at 50 nM concentrations and incubation of SCR for six days. FL, full-length; UT, 
untreated; SCR, scrambled sequence. GAPDH was used as a loading control. The gel images were 
cropped to highlight the MAPT-specific products and the corresponding house-keeping gene control 
GAPDH. The original images are shown in Figure S7 (Supplementary Material). 
i r . ( ) r s tative - r cts f t tr scri ts fr - c lls ft r
treat e t it a 4 50 co ce tratio a i c atio of for 24 , 48 , a six a s.
fro 4-treated samples was analysed using primer set 2. (B) Representative protein products of the
MAPT and GAPDH transcripts from SH-SY5Y cells after treatment with AO4 at 50 nM concentrations
and incubation of AO for 24 h, 48 h, and six days. RT-PCR products of the MAPT transcripts and
protein products of the MAPT and GAPDH transcripts from SH-SY5Y cells after treatment with SCR
at 50 nM concentrations and incubation of SCR for six days. FL, full-length; UT, untreated; SCR,
scrambled sequence. GAPDH was used as a loading control. The gel images were cropped to highlight
the MAPT-specific products and the corresponding house-keeping gene control GAPDH. The original
images are shown in Figure S7 (Supplementary Material).
Genes 2020, 11, 667 10 of 15
Genes 2019, 10, x FOR PEER REVIEW 10 of 15 
 
 
Figure 6. (A) Densitometry analysis of the tau expression obtained from western blot (three replicates) 
analysis after the treatment of SH-SY5Y cells with AO4 at 50 nM concentrations and incubation of 
AO4 for 24 h, 48 h, and six days. SH-SY5Y cells were treated with the scrambled control at a 50 nM 
concentration and incubation of six days. AO4 targets exon 4 of the MAPT transcript. The error bars 
represent the standard error of the mean. (B) Densitometry analysis of the tau expression obtained 
from western blot (three replicates) analysis after the treatment of SH-SY5Y cells with RNV563 at 400 
nM concentrations and incubation of DNAzyme for 24 h, 48 h, and six days. SH-SY5Y cells were 
treated with the scrambled control at a 400 nM concentration and incubation of six days. RNV563 
targets exon 9 of the MAPT transcript. The error bars represent the standard error of the mean. 
4. Discussion 
Hyperphosphorylated tau-based neurofibrillary tangle formation is believed to be a pathological 
hallmark for various tauopathies, including Alzheimer’s disease (AD). Although some early work 
focused on developing nucleic acid-based MAPT inhibitors, we envisioned revisiting this target for 
the development of novel nucleic acid molecules for efficient tau inhibition. This study screened 
various DNAzymes and AOs targeting different MAPT exons of the longest MAPT isoform—variant 
2. The primers used in this study for RT-PCR analysis only amplify certain MAPT variants (shown in 
Figure S9, Supplementary Material). Therefore, this study aimed to study the effects of the 
DNAzymes and AOs on the longest MAPT isoform, variant 2, which contains all of the exons and 
can thus be amplified by all of the primers used in this study. The effects on other variants can only 
present a partial picture, as not all primer sets amplify all six variants found in the adult brain. The 
MAPT transcripts detected by all of the primer sets used in this study are given in Table S6 
(Supplementary material). We screened various DNAzymes targeting different MAPT exons at two 
concentrations in SH-SY5Y cells (Figure S1, Supplementary Material) and the four identified 
candidates RNV559 (targeting exon 9), RNV561 (targeting exon 9), RNV563 (targeting exon 11), and 
RNV569 (targeting exon 13) efficiently downregulated the MAPT transcript. Further systematic 
evaluation at 400, 200, 100, and 50 nM concentrations identified RNV563 as the most efficient 
DNAzyme candidate. The RT-PCR full-length product of the RNV563-treated sample was sequenced 
and was demonstrated to align with the longest MAPT isoform, variant 2 (Figure S10, Supplementary 
Material), confirming that RNV563 downregulates the longest MAPT isoform. The variable 
efficiencies of downregulating the MAPT transcript observed in this study were similar to those 
observed in previous studies, including our work on DNAzymes targeting various regions of the 
ITGA4 mRNA [34], and others by Vester et al. and Kurreck et al [40]. These studies have suggested 
that the DNAzyme’s catalytic efficiency for cleaving its target may vary due to its dependence on the 
RNA’s tertiary structure. The RNA tertiary structure affects the accessibility of the purine-pyrimidine 
Figure 6. ( ) ensito etry analysis of the tau expression obtained fro estern blot (three replicates)
analysis after the treat ent of S -S 5 cells ith 4 at 50 n concentrations and incubation of
A 4 for 24 h, 48 h, and six days. S -S 5 cells ere treate ith the scra ble co trol at a 50 n
concentration and incubation of six days. 4 targets exon 4 of the APT transcript. he error bars
represent the standard error of the mean. (B) Densitometry analysis of the tau expression obtained from
western blot (three replicates) analysis after the treatm nt of SH-SY5Y cells with RNV563 at 400 nM
concentrations and incubation of DNAzyme for 24 h, 48 h, and six day . SH-SY5Y cells wer treat d
with the scrambled control at a 400 nM concentration and incubation of six days. RNV563 targets exon
9 of the MAPT transcript. he erro bars r present the standard error of the mean.
4. Discussion
Hyperphosphorylated tau-based neurofibrillary tangle formation is believed to be a pathological
hallmark for various tauopathies, including Alzheimer’s disease (AD). Although some early work
focused on developing nucleic acid-based MAPT inhibitors, we envisioned revisiting this target for
the development of novel nucleic acid molecules for efficient tau inhibition. This study screened
various DNAzymes and AOs targeting different MAPT exons of the longest MAPT isoform—variant 2.
The primers used in this study for RT-PCR analysis only amplify certain MAPT variants (shown in
Figure S9, Supplementary Material). Therefore, this study aimed to study the effects of the DNAzymes
and AOs on the longest MAPT isoform, variant 2, which contains all of the exons and can thus be
amplified by all of the primers used in this study. The effects on other variants can only present a
partial picture, as not all primer sets amplify all six variants found in the adult brain. The MAPT
transcripts detected by all of the primer sets used in this study are given in Table S6 (Supplementary
Material). We screened various DNAzymes targeting different MAPT exons at two concentrations
in SH-SY5Y cells (Figure S1, Supplementary Material) and the four identified candidates RNV559
(targeting exon 9), RNV561 (targeting exon 9), RNV563 (targeting exon 11), and RNV569 (targeting
exon 13) efficiently downregulated the MAPT transcript. Further systematic evaluation at 400, 200, 100,
and 50 nM concentrations identified RNV563 as the most efficient DNAzyme candidate. The RT-PCR
full-length product of the RNV563-treated sample was sequenced and was demonstrated to align
with the longest MAPT isoform, variant 2 (Figure S10, Supplementary Material), confirming that
RNV563 downregulates the longest MAPT isoform. The variable efficiencies of downregulating the
MAPT transcript observed in this study were similar to those observed in previous studies, including
our work on DNAzymes targeting various regions of the ITGA4 mRNA [34], and others by Vester
et al. and Kurreck et al [40]. These studies have suggested that the DNAzyme’s catalytic efficiency
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for cleaving its target may vary due to its dependence on the RNA’s tertiary structure. The RNA
tertiary structure affects the accessibility of the purine-pyrimidine cleavage sites to the DNAzyme and
may differ between different regions of the mRNA, which may explain the observed differences in
cleavage efficiencies.
The optimal arm length, the symmetry or asymmetry of the arms, and the GC content may all
affect the catalytic efficiency of the resulting DNAzyme, although how they affect the DNAzyme
activity is unclear. The target binding arm of the DNAzyme is an important factor in determining
the cleavage efficiency. Similar to our previously reported ITGA4-targeting DNAzyme RNV143 [34],
we designed DNAzymes targeting MAPT with asymmetrical arms. The most efficient first-generation
DNAzyme RNV563 was selected for further analysis by increasing and decreasing the arm lengths
based on the cleavage efficiency. Decreasing the arm length of DNAzyme RNV563 resulted in a
decreased cleavage efficiency in both SY-SY5Y cells and in the in vitro cleavage assay. The decreased
cleavage efficiency observed could be due to the decreased binding affinity of the shorter arm lengths
of the DNAzymes to their target RNA. In contrast, increasing the arm length of DNAyzme RNV563
resulted in a reduced cleavage efficiency in SH-SY5Y cells, but improved cleavage efficiency of the
synthetic RNA in the in vitro cleavage assay. Increasing the arm lengths of the DNAzyme RNV563
may increase the binding affinity to the target RNA, leading to an increased cleavage efficiency of the
synthetic RNA in vitro; however as shown by a previous study, cleavage of the shorter unstructured
RNA is more efficient than longer structured RNA and therefore, the in vitro cleavage efficiency may
not be a good representative of the in-cell environment and the synthetic RNA used in the in vitro
assay may not be a good representative of the longer and more complex structure of the RNA naturally
found in cells [37,41] Furthermore, an increased binding affinity may also lead to slower product
release that would inhibit or decrease the rate of multiple turnovers. Therefore, increasing the arm
length of the DNAzyme RNV 563 may have increased the binding affinity and decreased the rate of
multiple turnovers, and thus resulted in the decreased cleavage efficiency observed in SH-SY5Y cells.
This effect may not have been replicated in the in vitro cleavage assay as the amount of synthetic RNA
used for the in vitro cleavage assay is limited. Therefore, an accurate picture on the effect of increasing
the arm length of the DNAzyme on the rate of multiple turnovers may not be provided.
We also identified an exon-skipping AO that efficiently downregulates the MAPT transcript in this
study. AOs were designed to target regions in exons 1, 4, 5, 7, 9, and 12. Exon 1 contains the initiation
codon, and the skipping of 5, 7, 9, and 12 exons would induce a frameshift and generate a premature
stop codon (in exon 13, 9, 10/11, and 12, respectively). Inducing exon 4 skipping does not change the
reading frame; however, it is structurally important [5]. Furthermore, two amino acids, serine 113 and
threonine 123, that are known to be phosphorylated in AD, are found within exon 4, providing support
for the importance of exon 4 skipping [42,43]. AOs were designed to target these regions and block
the binding of splicing factors. AOs that targeted regions in exon 4 (AO4 and AO5) and exon 5 (AO6)
induced exon-skipping, but also showed downregulation of the MAPT transcript simultaneously.
The full-length product and exon-skipped RT-PCR products from AO4-treated samples were sequenced
to confirm that the exon-skipped product is missing exon 4 (Figure S11, Supplementary Material).
AO that targeted exon 12 (AO19) resulted in downregulation of the MAPT transcript, but was not
dose-dependent. AO4, AO5, and AO6 were designed to target the splicing enhancer region in the
MAPT isoform, variant 2, and therefore induce exon 4 and exon 5 skipping. Although exon skipping
and downregulation of the full-length product was observed in AO4-, AO5-, and AO6-treated cells,
the increase of exon-skipped product identified was not equivalent to the reduction in the full-length
product (Figure S4, Supplementary Material), indicating that exon skipping only accounts for part of
the loss of full-length products. On the other hand, whilst AO19 induced a significant knockdown
of the full-length product, it did not lead to visible exon skipping. Therefore, we speculate that in
addition to exon skipping-mediated downregulation of the full-length product, the steric bulkiness
imposed by the AOs that prevents the action of translational machinery and the non-sense mediated
decay (NMD) of mRNA resulting from exon skipping-induced premature termination codons are also
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possible mechanisms for MAPT knockdown. The AOs in this study were compared to a scrambled
control sequence, where the scrambled sequence was an AO with a random nucleotide sequence that
did not bind through complementary base pairing to any known gene used in our studies. However,
at 400 nM concentrations and higher, the scrambled control sequence seems to be toxic to the cells,
possibly due to off-target effects. However, this off-target effect at a 400 nM concentration may also
be due to the toxicity of having a 2’-OMePS backbone. This off-target effect may explain the reduced
MAPT transcript expression level compared to MAPT transcript expression in untreated cells only
observed at a 400 nM concentration (Figure 4C), and not at a 50 nM concentration (Figure 4D).
The most effective AO candidate, AO4 targeting exon 4, was found to be highly efficient in
downregulating the MAPT transcript compared to the lead DNAzyme candidate RNV563, which was
only found to be efficient at higher concentrations (58% knockdown at 400 nM), whereas AO4 was very
effective, even at a concentration as low as 6.25 nM (>60% knockdown). The lead AO and DNAzyme
candidates, AO4 and RNV563, were both further validated by testing the tau protein levels in SH-SY5Y
cells, which demonstrated a reduction in the tau level at 24 and 48 h, and this effect lasted at least
6 days after transfection with AO4, but not with RNV563. Tau has a relatively long half-life of about
12–14 h [44], explaining why the inhibition is seen at 24 and 48 h after AO4 and RNV563 treatment
(Figure 6). However, different from AO4, which recorded a gradual increase in tau protein suppression,
after 6 days of treatment of RNV563, the tau protein expression level displayed dramatic variation
between different tests. This phenomenon is probably because of the use of P3000 reagent during
the transfection of RNV563. As previously reported [45], the application of P3000, whilst ensuring a
better transfection of DNAzyme, comes with the problem of an increased cytotoxicity, especially for
long-term treatment such as six days. The observed cytotoxicity may have affected the quality of protein
extraction and resulted in unreliable western blotting results, as shown in Figure S8 of Supplementary
Material. Treatment of AO4 also resulted in a shorter protein product after 24 and 48 h of transfection
that was around 48 kDa (around 6–7 kDa shorter than the full-length product) (Figure 5). The shorter
protein product does not correspond to the exon-skipped product as the exon-skipped product should
only be 2–3 kDa smaller than the full-length product. However, it may correspond to the exon-skipped
product if the larger difference in size may be attributed to the loss of post-translational modifications,
in addition to the amino acids skipped from the full-length product. The AO4 needs to be further
validated and its effect on existing neurofibrillary tangles needs to be tested.
5. Conclusions
In summary, we have successfully identified an arm-loop-arm-type DNAzyme, RNV563, with a
10–23 catalytic motif that cleaves the MAPT transcript both in vitro and in SH-SY5Y cells, by screening
different DNAzyme constructs targeting various exons of the MAPT gene transcript. The DNAzyme,
RNV563, can downregulate the tau protein by more than 50%. We have also identified a 2’-OMePS
antisense oligonucleotide, AO4, that induces efficient exon 4 skipping and downregulates the MAPT
transcript in SH-SY5Y cells at concentrations as low as 6.25 nM, and downregulates the tau protein by
more than 70%. We believe that our findings will contribute towards tau targeting drug development
and help to improve the knowledge in the field.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/11/6/667/s1;
Table S1. List of first-generation DNAzymes and their sequences; Figure S1. Representative RT-PCR products
of the MAPT and GAPDH transcripts from SH-SY5Y cells after treatment with DNAzyme at 400 and 50 nM
concentrations; Figure S2. Representative RT-PCR products of the MAPT and GAPDH transcripts from SH-SY5Y
cells after treatment with DNAzyme at 400, 200, 100, and 50 nM concentrations; Figure S3. Representative
RT-PCR products of the MAPT and GAPDH transcripts from SH-SY5Y cells after treatment with DNAzyme at
400, 200, 100, and 50 nM concentrations; Table S2. The average activity of second-generation DNAzymes (at a
400 nM concentration) in SH-SY5Y cells (knockdown of the MAPT transcript); Figure S4. In vitro cleavage of
the FAM-conjugated MAPT RNA template composed of the exon 11 region (34 nucleotides) by RNV563 and its
derivatives; Table S3. List of 2’-OMePS AOs and their sequences; Figure S5. Representative RT-PCR products of the
MAPT transcripts from SH-SY5Y cells after treatment with splice-modulating AOs at 400 and 50 nM concentrations;
Figure S6. A. Representative RT-PCR products of the MAPT transcripts from SH-SY5Y cells after treatment with
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AO4, AO5, AO6, and AO19 at 400, 200, 100, and 50 nM concentrations. B. Representative RT-PCR products of
the MAPT and GAPDH transcripts from SH-SY5Y cells after treatment with AO4, AO5, AO6, and AO19 at 50,
25, 12.5, and 6.25 nM concentrations; Figure S7. A. Representative RT-PCR products of the MAPT transcripts
from SH-SY5Y cells after treatment with an AO4 50 nM concentration and incubation of AO for 24 h, 48 h, and six
days. B. Representative protein products of the MAPT and GAPDH transcripts from SH-SY5Y cells after treatment
with AO4 at 50 nM concentrations and incubation of AO for 24 h, 48 h, and six days; Figure S8. A. Representative
protein products of the MAPT and β-actin transcripts from SH-SY5Y cells after treatment with AO4 at 50 nM
concentrations and incubation of AO for 24 h, 48 h, and six days. AO4 targets exon 4 of the MAPT transcript.
The scrambled control was used at a 50 nM concentration and samples were collected after six days of transfection.
B. Representative protein products of the MAPT and β-actin transcripts from SH-SY5Y cells after treatment with
RNV563 at 400 nM concentrations and incubation of DNAzyme for 24 h, 48 h, and six days. RNV563 targets exon
9 of the MAPT transcript. The scrambled control was used at a 50 nM concentration and samples were collected
after six days of transfection; Table S4. List of primers used, their sequences, and the expected product lengths;
Table S5. The PCR conditions for each primer set; Table S6. List of primers used, their binding co-ordinates,
the expected full-length product size, and the exon-skipped product size; Figure S9. Exon map of the MAPT
variants found in the human brain and the primer binding sites of the primer sets used in this study; Figure S10.
Sequence alignment of the full-length band (968 bp product) from RNV563-treated samples and the longest MAPT
isoform, variant 2; Figure S11. A. Exon 3-Exon 5 region of the sequencing of the FL (307 bp) product from the
AO4-treated sample. B. Exon 3-Exon 5 region of the sequencing of the exon-skipped (241 bp) product from the
AO-treated sample.
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42. Šimić, G.; Babić Leko, M.; Wray, S.; Harrington, C.; Delalle, I.; Jovanov-Milošević, N.; Bažadona, D.; Buée, L.;
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